Noninfectious intermediate, posterior, or panuveitis: results from the retrospective, observational, international EyeCOPE study

• Autor(a) principal: Michal Kramer
• Data de Publicação: 2021
• Outros Autores: Michaela Brichova, Ilknur Tugal-Tutkun, Mykola Panchenko, Natali Weniger Spelling Gormezano, Franziska Koenigsbauer, Pablo Franco, Cristina Muccioli, Murat Hasanreisoglu, Ayse Cigdem Altan, Radgonde Amer, Matthias Becker, Florian Balta, Daniel Branisteanu, Gustavo Budmann, Thiago George Cabral Silva, Muge Pinar Cakar Ozdal, Sonja Cekic, Alina Popa Cherecheanu, Carmen Chiotan, Vivian Cristina Costa Afonso, Cristóbal Couto, Ciprian Danielescu, Daniel Vitor de Vasconcelos Santos, Assel Doshakanova, Luis Jose Escaf, Jarmila Fabiánová, Justus Gerhard Garweg, Aida Geamanu, Tamar Hareuveni, Jarmila Heissigerova, Aleksandra Ilic, Svetlana Jovanovic, Sanda Jurja, Sibel Kadayifcilar, Esra Kardes, Tea Čaljkušić Mance, Hernando Antonio Muñeton Abadia, Ana Oros, Hilal Eser Ozturk, Yilmaz Ozyazgan, Aleksandra Radosavljevic, Carlos Mario Rangel, Ali Osman Saatci, Ariel Schlaen, Maja Vinković, Nenad Vukojević, Fatime Nilufer Yalcindag, Melike Balikoglu Yilmaz, Suzan Guven Yilmaz, Oleksandra Zborovska
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1007/s40123-021-00351-4; http://hdl.handle.net/1843/54939; https://orcid.org/0000-0001-7154-1427; https://orcid.org/0000-0002-4020-453X; https://orcid.org/0000-0003-0613-1776; https://orcid.org/0000-0002-6870-6187; https://orcid.org/0000-0002-6747-2024
• topic: Corticosteroid disease burden; Disease characteristics; Immunosuppressants; Noninfectious uveitis; Patient-reported outcomes; Corticosteroides; Atributos de doença; Imunossupressores; Uveíte; Pan-uveíte; Medidas de resultados relatados pelo paciente

Introduction: The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. Methods: This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records. Results: Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts. Conclusions: Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.